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Research into extracellular vesicles (EV)
has yielded important biological insights
and raised the prospect of developing
novel diagnostics and therapeutics for a
wide range of pathologies. As with other
emerging and transformative fields in
research, it will require a broad, support-
ive base for EV research to mature and to
develop clinical application. Here, we iden-
tify several focus areas to further improve
reproducibility and reliability specifically
for EV research and make recommenda-
tions for minimal experimental guidelines,
transparency tools, reference materials,
validation, identification of contaminants,
data sharing, coaching through education,
and funding opportunities.
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Extracellular vesicle research
and applications
Extracellular vesicles (EV) are membrane-
enclosed nanoparticles that contain proteins,
nucleotides, lipids and metabolites. Eukary-
otic cells secrete EV through orchestrated
plasma membrane budding or fusion of
multi-vesicular endosomes with the plasma
membrane. A third mechanism of EV gene-
sis takes place during controlled cell death
when cells fragment into apoptotic bodies
(van Niel et al, 2018). EV are not unique to
eukaryotic cells: both Gram+ and Gram
bacteria can release EV by outward budding
of the prokaryotic membrane (Toyofuku
et al, 2019). EV have been attributed biologi-
cal functions in physiology and diseases
such as cancer and cardiovascular, neuro-
logical, and immune-related disorders.
Although these vesicles were discovered
more than 40 years ago, it was only during
the past decade that scientists began to
understand their function in cell-to-cell
communication on the molecular level and
their role in physiology and pathology.
Extracellular vesicles have been identi-
fied in any human biofluid, including blood,
and therefore offer a possibility for easy and
efficient diagnosis and monitoring of disease
progression—potential applications in
cancer diagnostics are one example of immi-
nent use. Bulk EV isolated from blood
followed by glypican-1 protein single-
marker analysis can identify early-stage
pancreatic cancer; EV subtypes isolated
using antibody cocktails that target EV
surface proteins showed higher specificity
for pancreatic cancer compared to single-
marker isolation. Similarly, EV hold great
potential for developing new therapies or
delivery systems for existing drugs. EV from
selected eukaryotic and prokaryotic cell
types have already been used as therapeutic
agents in oncology, regenerative medicine,
and for vaccination. As a vehicle for drug
delivery, siRNA-loaded EV show remarkable
efficacy in treating multiple animal models
of cancer.
Given their potential for diagnosis and
therapy, EV-related research and applica-
tions have attracted considerable commercial
interest and investment. The number of EV-
related patents has been increasing steadily
during the past decade, and the production
of EV at therapeutically relevant quantities
and with good manufacturing practices
(GMP) is underway. The global market for
EV-based diagnostics and therapeutics is
projected to grow from US$25 million in
2018 to US$180 million in 2023—a 5-year
compound annual growth rate (CAGR) of
48.4% (https://www.bccresearch.com/ma
rket-research/biotechnology/exosome-dia
gnostics-and-therapeutics-global-markets-re
port-bio149b.html).
......................................................
“Although these vesicles were
discovered more than 40 years
ago, it was only during the
past decade that scientists
began to understand their
function in cell-to-cell commu-
nication on the molecular level
and their role in physiology
and pathology.”
......................................................
However, the plethora of methods to
separate and characterize EV, the intrinsic
heterogeneity of EV subtypes with varying
size (from 40 to > 500 nm), molecular
patterns (Tkach et al, 2017), their origin
(Tulkens et al, 2018), and the complexity of
biofluids present considerable challenges for
rigorous and reproducible research as a
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basis for clinical applications (Van Deun
et al, 2017). We therefore discuss potential
areas of concern and propose recommenda-
tions to cope with these problems and chal-
lenges. To be useful, recommendations must
be widely embraced by the community,
which requires further discussion and
advice. This commentary will hopefully
encourage said discussion and provide
useful steps for transforming fundamental
EV research into clinical applications.
Situating the areas of concern
There is no one-size-fits-all method for
analyzing EV. Biofluids are complex
mixtures that contain many components
some of which share biochemical and physi-
cal characteristics with EV (Simonsen, 2017).
Different methods that separate EV with vari-
able purity are used and identify method-
dependent functions or biomarkers. Some
separation methods have low selectivity and
yield multiple EV subtypes, while others are
more selective to include or exclude specific
EV subtypes. Some biophysical characteriza-
tion methods are not able to measure smaller
sized EV subtypes and thereby underesti-
mate EV numbers, whereas others fail to
discriminate between EV and contaminants
—ribo- or lipoproteins and other aggregates
—and potentially overestimate the quantity
of EV. Additionally, unlike inorganic metal
nanoparticles that generally have the same
size in the “wet” and “dry” states, EV can
undergo substantial size changes, depending
on the analysis method used—for instance,
electron microscopy (dry state) versus
hydrodynamic radius calculation from
dynamic light scattering analysis (wet state).
As such, interpretation of EV data remains
far from easy and straightforward and
requires proper training and experience of
researchers but also reviewers and editors.
The complex composition of biofluids
requires branched development of comple-
mentary separation and characterization
methods to unlock the secrets of EV.
Comparing methods and transparency in
reporting experimental parameters will be
indispensable to direct and understand this
development. Methodological comparison
and cross-laboratory studies also require
reference materials to deal with technical
variability and reveal biological differences.
Transparency is necessary to improve the
exchange of (meta)data and allow system-
atic comparison between approaches.
A supporting ecosystem based on
eight pillars
The EV research community has already
started initiatives to cope with some of these
challenges (Van Deun et al, 2017). However,
the most important missing element is that
all areas of concern are connected and inter-
dependent. Dealing with one or two of these
individually will not be sufficient to move
the field forward. It is their complementary
and combined aspect that will lead to
synergy and changes. We therefore propose
a supporting ecosystem based on eight
pillars to make the field aware of critical
issues and present solutions (Fig 1).
Minimal information guidelines
There are established guidelines for select-
ing and interpreting separation and charac-
terization methods for EV; these are useful
for researchers as well as reviewers who
need to provide realistic and reasonable
critique of papers focused on EV. These
guidelines were first published in 2014 and
updated in 2018. Minimal information
guidelines are intertwined with experience-
based advice and position papers with a
focus on biofluid collection, storage, and
use for EV analysis, clinical grade EV
preparation, and EV-associated RNA
analysis. Importantly, guidelines should be
focused on parameters and technologies
that are accessible to most research teams
and receive broad consensus, which is a
necessity for broad implementation.
Transparency and tools to
promote transparency
The plethora of methods and protocols can
be confusing, but it is probably unavoidable,
given the diverse nature of EV and innova-
tive character of research. In many cases,
scientists find that their exact requirements
are not met by current tools and often have
to create custom solutions. Protocols should
therefore be open and transparent, so that
all scientists can understand them, recognize
their value, and can adhere to them, even if
the technology advances—as will be the
case.
To cope with this variety of methods, the
community needs to be aware of essential
experimental parameters and to report them
so anyone can understand each experiment
and reproduce the results. Specifically, the
EV-TRACK knowledgebase (Van Deun et al,
2017), an online open-access resource to
track and organize data on EV separation
and characterization, is therefore suitable to
monitor progress in the field in a standard-
ized format. The current set-up includes a
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Figure 1. Radar plot depicting eight pillars of a supporting ecosystem to mature EV into clinical
application.
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checklist of nine essential experimental
parameters that are bundled into an EV-
METRIC (http://evtrack.org/) to improve
transparency. Interpretation of reported data
would be further improved by using
Research Resource Identifiers (RRID) to
identify key resources, that is, reagents,
tools, and materials (https://scicrunch.org/
resources). RRID meet three key criteria:
they are machine-readable, free to generate
and access, and are consistent across
publishers and journals.
......................................................
“The complex composition of
biofluids requires branched
development of complementary
separation and characteriza-
tion methods to unlock the
secrets of EV.”
......................................................
Admittedly, both the implementation of
checklists (such as EV-METRIC) and RRID
may be time-consuming for authors, but it
will improve reporting of essential experi-
mental parameters and unambiguous
resource identification, two crucial aspects
for increasing reproducibility. In addition,
the EV-TRACK knowledgebase, as it is avail-
able to the whole community, could funda-
mentally shift our interaction with the
literature and may facilitate protocol design
and reassessment and reuse of published
data. No doubt, there will be challenges to
incorporate EV-TRACK into large-scale prac-
tice. A main aspect is the available resources
to upload the massive EV-related data (cur-
rently more than 1,000 research papers/
year). Uploading could be done by one (or
more) of many parties: authors, journal
staff, third-party scientists, or even algo-
rithms. Prospective manual upload is feasi-
ble when authors submit a paper for peer
review. However, manual upload is difficult
retrospectively given the massive number
of EV-related papers already published.
Automated, artificial intelligence-driven
approaches may come to the rescue. Finally,
the performance of the EV-TRACK pipeline
itself would need to be evaluated.
Reference materials for normalization
or calibration
Biological reference materials are available
but are currently not or poorly trackable
and are indistinguishable from sample EV.
Synthetic reference materials, such as silica
beads, are particularly useful for the cali-
bration of optical EV detection methods,
but have poor application for normaliza-
tion because they do not have a wide size
distribution, surface and luminal biomole-
cules, and different density characteristics.
Ideally, EV biomimetics, with similar size,
density, and biochemical composition but
easily distinguishable from sample EV
(e.g., through a fluorescent probe), should
be available for research. Major challenges
for biological reference EV are their large
complicated macromolecular structure;
their heterogeneity; and their complicated
production and purification. EV reference
materials must also come in narrow size
ranges to calibrate characterization meth-
ods and to evaluate size specificity of
separation methods. Efforts should be
stimulated to design robust control refer-
ence materials by academics, and commer-
cial and quality assurance program
providers. Their subsequent promotion is
crucial to obtain maximum understanding
and impact, and to facilitate consistent
application.
Validation: comparison of separation and
characterization methods, interlaboratory
studies, and benchmarking of
novel methods
Several technologies have been developed
to separate or measure EV, but there are
no appropriate and quantifiable perfor-
mance metrics for these technologies,
which hampers informed selection of the
most appropriate method for the particular
study objectives. Studies are needed to
objectively assess technology performance
in terms of repeatability, sensitivity, accu-
racy, specificity, and efficiency. Interlabora-
tory evaluation to assess reproducibility
and benchmarking of novel methods is of
great importance before widespread use or
clinical implementation. The International
Society for Extracellular Vesicles (ISEV)
and a number of national EV societies may
stimulate researchers to perform validation
studies. We consider the establishment of
EV core facilities (https://www.helsinki.fi/
en/researchgroups/extracellular-vesicles/ev-
core) and the use of automated liquid hand-
lers as important contributors to facilitate
this interlaboratory validation and repro-
ducibility.
Identification of true contaminants versus
true content
Generally, a short list of EV contaminant
proteins, lipids, or RNA species is not available
to the community. Although this knowledge is
essential for a sensitive and selective use of EV
in clinics and although efforts are underway to
compile such a list they are not yet widely
implemented as evidenced from EV-TRACK
data. Owing to the vesicular nature of EV, true
content is more easily identified as transmem-
brane or GPI-anchored proteins or cytosolic
proteins with lipid or membrane protein-
binding ability. No such data are available for
other classes of proteins, lipids, or nucleotides.
Another and poorly described source of
complexity is the likely presence of a corona
of various molecules on the EV surface. In
particular, plasma proteins, such as comple-
ment factors, immunoglobulins, or lipopro-
teins, are frequently reported to be part of a
corona that may also involve nucleotides.
Knowing that some methods may co-isolate
true contaminants while other methods
cause the loss of true content in the form of
corona proteins/nucleotides, progress in this
area may be the most challenging for the
years ahead.
(meta)data sharing and annotation
Vesiclepedia (http://www.microvesicles.
org) is a web-based compendium of proteins,
RNA, lipids, and metabolites that are identi-
fied in EV (Kalra et al, 2012). Studies in Vesi-
clepedia are currently annotated with an
EV-METRIC for transparent reporting on EV
isolation and characterization methods
(Pathan et al, 2018). This is a major
improvement, because it informs the end
user about certain standards in EV separa-
tion characterization methods and allows
stringent searches can be performed. Yet,
the data sets (protein–RNA–lipid–sugars–
metabolites) generated in EV research
currently remain isolated owing to the lack
of a data-sharing system. In addition, raw
images and videos—for example, electron
microscopy and nanoparticle tracking analy-
sis (NTA)—are generally not reported in
publications and remain an untapped poten-
tial for data reanalysis. Thus, a centralized
data repository system combined with
knowledge of experimental parameters (EV-
TRACK annotation) will allow novel
approaches to maximize the utility of the
collected data.
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Coaching through training and education
Hands-on courses and didactic programs for
early-stage and experienced researchers by
educational days or workshops is a recent
focus to advance education and experi-
ence (https://www.embl.de/training/eve
nts/2019/EXO19-01/; https://www.isev.
org/page/ISEV2018Education; https://www.
isev.org/page/ChinaWorkshop).
These courses, combined with trans-
parency tools, will help to optimize method-
ological rigor and reproducibility in EV
research. Although we realize that instruc-
tor-led training would be limited (hands-on
EMBL courses reach 25 persons/year; ISEV
educational days reach 2,000 persons/
year), online videos (YouTube, JoVE) or
massive open online courses (https://
www.coursera.org/learn/extracellular-vesic
les) may greatly enhance the target audi-
ence. As transparency is an issue in all
scientific fields, the NIH provides free online
educational material as part of a training
initiative (https://www.nih.gov/research-tra
ining/rigor-reproducibility/training#Module
s). Such efforts should be incorporated into
basic scientific education and resources such
as the European Open Science Cloud.
Although governments and national and
international EV societies play an essential
role in didactic programs and training, each
principal investigator should take responsi-
bility as well. For example, laboratory-based
journal clubs are invaluable training formats
that allow discussion of science, methodol-
ogy, and transparency in the context of a
specific publication and strongly influence
the perception of a publication by young
and experienced researchers.
Funding opportunities to stimulate
benchmarking and interlaboratory studies
Scientific rigor is the strict application of the
scientific method to ensure unbiased and
well-controlled experimental design,
methodology, analysis, interpretation, and
reporting of results. Both the United States
and Europe started funding opportunities to
promote rigor, reproducibility, and metrol-
ogy in EV isolation, characterization, and
computational analysis (https://grants.
nih.gov/grants/guide/pa-files/PAR-16-277.
html; https://msu.euramet.org/calls.html).
Although any efforts to improve repro-
ducibility will require a measured invest-
ment in capital and time, the long-term
benefits to society derived from increased
scientific fidelity will greatly exceed the
upfront costs (Freedman et al, 2015).
Conclusion
The eight actionable suggestions outlined
above provide a supporting ecosystem to
increase rigor and reproducibility in EV
research. As in each ecosystem, these pillars
are interdependent. Reference materials and
validation experiments will support identifi-
cation of contaminants. This knowledge will
be implemented in guidelines that mandate
transparent reporting for data sharing. The
community needs to be coached and
educated about the areas of concern and
respective solutions. Financial support is a
prerequisite to move the field forward.
This ecosystem will ensure a steady
supply of innovative, reliable, and repro-
ducible discoveries to translate EV research
into societal benefits. Early clinical successes
with bacterial-derived EV as a vaccination
strategy raise tremendous hopes that EV
may indeed reach wide clinical application.
The road toward success will come more
rapidly with the full engagement of the
entire EV research community.
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